Dabigatran EMA - product-specific guide [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-02-14 12:52  – Posting: # 19920
Views: 605

Hi nobody,

» » Aren’t you notoriously shouting “It’s the originator, stupid…”?
» Could you elaborate on this. No clue what this might mean.

See there.

» If you want a duel, choose your weapon
» :hungry:


» » I’m more concerned about the first footnote in the guidance […]. Was the EMA’s PKWP not aware of the the FDA’s guidance?
» Narrow therapeutic range... maybe in the USA. In the EU there are no mass tort trials...

I don’t like the idea that someone widens the limits for this stuff.

» What buys you the widening for Cmax, when both parameters are highly variable? :confused:

Business as usual in all jurisdictions following the EMA’s strange approoach (i.e., WHO; ASEAN States, Australia, Brazil, Egypt, the Russian Federation, the Eurasian Economic Union, New Zealand). At least the WHO initiated a pilot phase for scaling the AUC. For HC widening the limits for AUC is acceptable (no big deal for Cmax; only the PE within 80.0–125.0%).

Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,404 posts in 4,122 threads, 1,323 registered users;
online 20 (1 registered, 19 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 16:42 UTC

No rational argument will have a rational effect on a man
who does not want to adopt a rational attitude.    Karl R. Popper

BEBAC Ing. Helmut Schütz